FindTrial
Sign In

Assessment of the value of hyoscine butylbromide (Buscopan®) in optimising image quality for patients undergoing pelvic magnetic resonance imaging

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN56242729
Enrollment
Unknown
Registered
2004-09-30
Start date
2004-01-20
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Magnetic resonance imaging (MRI) Not Applicable Imaging procedure

Interventions

Before pelvic magnetic resonance imaging patient will received either intravenous hyoscine butylbromide or a placebo.

Sponsors

Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing pelvic magnetic resonance imaging.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Overall image quality and visualisation of individual pelvic structures and visualisation of tumours on MR images, both with and without Buscopan®.—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026